


Journal Pre-proof

Polygenic prediction of atopic dermatitis improves with atopic training and filaggrin factors

Christopher H. Arehart, BS, Michelle Daya, PhD, Monica Campbell, MS, Meher Preethi Boorgula, MS, Nicholas Rafaels, MS, Sameer Chavan, MS, Gloria David, PhD, Jon Hanifin, MD, Mark K. Slifka, PhD, Richard L. Gallo, MD PhD, Tissa Hata, MD, Lynda C. Schneider, MD, Amy S. Paller, MD, Peck Y. Ong, MD, Jonathan M. Spergel, MD, Emma Guttman-Yassky, MD PhD, Donald Y.M. Leung, MD, PhD, Lisa A. Beck, MD, Christopher R. Gignoux, MS, PhD, Rasika A. Mathias, Sc.D., Kathleen C. Barnes, PhD



PII: S0091-6749(21)00895-2

DOI: <https://doi.org/10.1016/j.jaci.2021.05.034>

Reference: YMAI 15146

To appear in: *Journal of Allergy and Clinical Immunology*

Received Date: 12 August 2020

Revised Date: 26 April 2021

Accepted Date: 20 May 2021

Please cite this article as: Arehart CH, Daya M, Campbell M, Boorgula MP, Rafaels N, Chavan S, David G, Hanifin J, Slifka MK, Gallo RL, Hata T, Schneider LC, Paller AS, Ong PY, Spergel JM, Guttman-Yassky E, Leung DYM, Beck LA, Gignoux CR, Mathias RA, Barnes KC, Polygenic prediction of atopic dermatitis improves with atopic training and filaggrin factors, *Journal of Allergy and Clinical Immunology* (2021), doi: <https://doi.org/10.1016/j.jaci.2021.05.034>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Polygenic prediction of atopic dermatitis improves with atopic training and filaggrin factors

Authors:

Christopher H. Arehart BS¹

Michelle Daya PhD¹

Monica Campbell MS¹

Meher Preethi Boorgula MS¹

Nicholas Rafaels MS¹

Sameer Chavan MS¹

Gloria David PhD²

Jon Hanifin MD³

Mark K. Slifka PhD³

Richard L. Gallo MD PhD⁴

Tissa Hata MD⁴

Lynda C. Schneider MD⁵

Amy S. Paller MD⁶

Peck Y. Ong MD⁷

Jonathan M. Spergel MD⁸

Emma Guttman-Yassky MD PhD⁹

Donald Y. M. Leung MD, PhD¹⁰

Lisa A. Beck MD¹¹

Christopher R. Gignoux MS, PhD¹

24 Rasika A. Mathias Sc.D.^{12*}

25 Kathleen C. Barnes, PhD^{1*}

26 * Equally contributing Senior Authors

27

28 Address correspondence to: Kathleen C. Barnes,

29 University of Colorado Anschutz Medical Campus

30 13001 E. 17th Place, Room 5330A, Aurora, CO 80045 | Mail Stop F563

31 E: Kathleen.Barnes@cuanschutz.edu | P: 303-724-9734

32

33 *Affiliations:*

34 ¹ University of Colorado Anschutz Medical Campus, Aurora, CO

35 ² Rho, Inc., Durham, NC

36 ³ Oregon Health & Science University, Portland, OR

37 ⁴ University of California San Diego, San Diego, CA

38 ⁵ Boston Children's Hospital, Boston, MA

39 ⁶ Northwestern University and Ann & Robert H. Lurie Children's Hospital of Chicago,
40 Chicago, IL

41 ⁷ Division of Clinical Immunology and Allergy, Children's Hospital Los Angeles and
42 University of Southern California, Los Angeles.

43 ⁸ Philadelphia, Department of Pediatrics, Perelman School of Medicine at University of
44 Pennsylvania, Philadelphia, PA

45 ⁹ Icahn School of Medicine at Mount Sinai, New York, NY

46 ¹⁰ National Jewish Health, Denver, CO

¹¹ University of Rochester Medical Center, Rochester, NY

¹² Johns Hopkins University Department of Medicine, Baltimore, MD

Funding:

Funding for this work was provided by NIH/NIAID U19 AI117673, The Atopic Dermatitis Research Network and the Oregon National Primate Research Center grant, 8P51 OD011092 (MKS).

Competing interests:

We are declaring the following competing interests: ASP has been a consultant for AbbVie, Boehringer Ingelheim, Dermira, Eli Lilly, Forte, Galderma, LEO Pharma, Novartis, Pfizer, Regeneron, and Sanofi Genzyme, and investigator for AbbVie, Eli Lilly, Incyte, LEO Pharma, Novartis, and Regeneron. CRG has stock in 23andMe. KCB receives royalties from UpToDate. LAB is a consultant for Abbvie, Allakos, Astra-Zeneca, Benevolent AIBio, Incyte, Janssen, Leo Pharma, Lilly, Naos Bioderma, Novartis, Pfizer, Principia Biopharma, Rapt Therapeutics, Regeneron, Sanofi/Genzyme, Sanofi-Aventis, UCB and Vimalan and an investigator for Abbvie, Astra-Zeneca, Kiniksa, Leo Pharma, Pfizer, Regeneron and Sanofi and has stock in Medtronics, Moderna and Gilead. LCS is an investigator for Regeneron and DBV Technologies, a consultant for Amagma, Alladapt, and Ukko and has grants from Genentech and Pfizer. RLG is a board member of MatriSys, Bioscience, has received a consulting fee from Sente, has pending grants through Novan and Regeneron, and has stock in Sente and MatriSys. The rest of the authors declare that they have no relevant conflicts of interest.

Word Count: 4503

Capsule Summary: This study presents a thorough polygenic risk scoring framework for identifying individuals with high genetic risk for atopic dermatitis (AD).

Key words: atopic dermatitis; polygenic risk score; atopic march; allergic disease; genetic architecture; filaggrin; disease prediction; genetic predisposition

Abbreviations: Atopic Dermatitis (AD), Polygenic Risk Score (PRS), Polygenic Score (PGS), Genome-wide Polygenic Score (GPS), Genetic Risk Score (GRS), Genome Wide Association Study (GWAS), Epidermal Differentiation Complex (EDC), Atopic Dermatitis Research Network (ADRN), EARly Genetics and Lifecourse Epidemiology (EAGLE), Filaggrin (*FLG*), atopic-factor (α -factor), Linkage Disequilibrium (LD), Odds Ratio with 95% Confidence Interval (OR [95% CI]), Area Under the Curve (AUC), European Americans (EA), Multi-Ethnic Global Array (MEGA), Principal Component Analysis (PCA), Effective Sample Size (Neff), P-value Thresholding (P+T), Eczema Area and Severity Index (EASI), Rajka Langeland (RL), Likelihood-Ratio-Test (LRT), Whole Genome Sequencing (WGS)

Abstract

Background: While numerous genetic loci associated atopic dermatitis (AD) have been discovered, to date, work leveraging the combined burden of AD risk variants across the genome to predict disease risk has been limited.

Objective: This study aims to determine if polygenic risk scores (PRSs) relying on genetic determinants for AD provide useful predictions for disease occurrence and severity. We also explicitly test the value of including genome wide association studies (GWASs) of related allergic phenotypes and known filaggrin (*FLG*) loss-of-function (LOF) variants.

Methods: AD PRSs were constructed for 1,619 European American (EA) individuals from the Atopic Dermatitis Research Network (ADRN) using an AD training dataset and an atopic training dataset including AD, childhood onset asthma, and general allergy. Additionally, whole genome sequencing data were used to explore genetic scoring specific to *FLG* LOF mutations.

Results: Genetic scores derived from the AD-only GWAS were predictive of AD cases (PRS_{AD}: OR [95% CI] = 1.70 [1.49, 1.93]). Accuracy was first improved when PRSs were built off the larger atopy GWAS (PRS_{AD+}: OR = 2.16 [1.89, 2.47]) and further improved when including *FLG* LOF mutations (PRS_{AD++}: OR = 3.23 [2.57, 4.07]). Importantly, while all three PRSs correlated with AD severity, the best prediction was from PRS_{AD++} which distinguished individuals with severe AD from controls with OR = 3.86 [2.77, 5.36].

Conclusion: We demonstrate how PRSs for AD that include genetic determinants across atopic phenotypes and *FLG* LOF variants may be a promising tool for identifying individuals at high-risk for developing disease and specifically severe disease.

Clinical Implication: A genetic risk model combining AD and atopy related genetic variants with *FLG* loss-of-function indicators could identify high-risk neonates for targeted therapies to prevent the onset (or severity) of AD.

Introduction

Atopic dermatitis (AD) is a common skin disease often characterized by pruritus, dryness and eczematous, erythematous skin lesions. AD has a broad health impact as it is estimated to be prevalent in 6-11% of the United States population^{1, 2}, is more common in children than adults, and affects individuals worldwide³. Reducing the burden of AD would be financially beneficial to both individuals and the overall health care system. The national cost of AD has been conservatively estimated to be \$5.297 billion annually^{4, 5}, and survey results report the median affected adult spends \$600 out of pocket on AD related expenses per year⁶. These large nationwide and personal costs are important to contextualize among the profound psychological impacts and decreased quality of life associated with AD^{7, 8}.

Environmental factors such as climate, pollution, food, and use of personal care products are considered to play a role in disease development^{9, 10}, but AD has been noted for its especially high heritability (71-90%)¹¹⁻¹³ among atopic diseases suggesting a prominent role for genetic risk factors. AD often precedes the onset of other atopic diseases such as allergic rhinitis, food allergy, and asthma^{14, 15} described as the atopic march, and importantly, there is shared genetic etiology between asthma, AD, and allergic rhinitis^{16, 17}. A recent review supports these overlaps in AD and asthma genetic loci with food allergy, notably a non-specific role for *FLG* (filaggrin) loss-of-function (LOF) variants, and HLA alleles¹⁸. The common progression from AD to other atopic conditions further highlights the importance of identifying at-risk individuals for targeted interventions that might reduce the risk of AD, mitigate severity, or lower the propensity to march towards other comorbid conditions.

AD persists on a spectrum, and the improvement patients may attain through treatment options is often dependent on the severity of the disease¹⁹. In addition, patients with AD are uniquely susceptible to cutaneous infections²⁰ including the viral complication known as eczema herpeticum and increased frequency of bacterial colonization and infection with *Staphylococcus aureus*^{21, 22}. Moderate and severe AD is characterized by skin patches that are dry, red, inflamed, and itchy, and the resulting limitations to lifestyle (e.g. avoidance of social interaction, sleep disturbance) have been associated with indicators for decreased quality of life⁸.

Polygenic risk scores (PRSs) are a summation of an individual's particular genetic variants weighted by their disease-specific effect sizes, in which these effect sizes are typically derived from an external and independent genome wide association study (GWAS). These scores are becoming more accurate as GWAS sample sizes increase²³, and have demonstrated potential clinically utility²⁴⁻²⁶. Genetic scores using < 30 variants²⁷⁻²⁹ and PRSs using hundreds of variants³⁰ have recently been applied to allergic phenotypes including AD. However, extensive investigation into PRS modeling methods specific to the genetic architecture of AD and analysis of the associations of these scores with measures of AD severity has yet to be addressed.

We aim to build upon these primary frameworks of AD prediction through exploring the contribution of genetic signals across allergic phenotypes, PRS model types, thresholds for variant inclusion, *FLG*-specific genetic components, and an emphasis on the severity of AD. To the best of our knowledge, such an exhaustive score-based application of genetic data has not yet been applied to AD, despite the potential utility to inform preventative treatment options³¹⁻³⁴ of high-risk individuals. It is

important to frame our findings in the context of the following: 1) the genetic component for AD is complex³⁵⁻³⁷ and prediction methods have yet to be optimized, 2) a meta-analysis of AD GWASs has identified 27 AD risk loci across 15 chromosomes with gene-sets enriched for innate immune cell signaling and T-cell polarization¹¹ 3) among these risk loci, loss-of-function mutations in *FLG* which result in epidermal barrier deficiency are the strongest known risk factors^{11, 38} 4) AD fits into the larger genetic framework of the atopic march (e.g. childhood onset asthma associations showed enrichment for dysregulated allergy and epithelial barrier function genes, suggesting broader connections between genetic risk factors for allergic disease and AD³⁹) 5) accurate methods for identifying high-risk individuals at birth who might benefit from prophylactic treatments currently under investigation^{32-34, 40-46}. Thus, we compare methods involving external genome-wide training datasets for three atopic phenotypes (AD, childhood onset asthma, and general allergic disease) along with a score pertaining to four specific variants widely studied for their strong association with AD and loss-of-function in the *FLG* gene⁴⁷⁻⁴⁹. Through focusing on the genetic components of AD we demonstrate notable differentiation between cases and controls and illustrate strong associations between PRSs and measures of AD severity.

Materials and Methods

Our overall study design is summarized in Figure 1. Briefly, we used GWAS summary statistics from large external studies (Table S1) to derive several PRS models for AD prediction. For each of these external training datasets, we perform model selection tailored to the genetic architecture of AD. The first model we name PRS_{AD} (Figure 1: orange) as it uses a meta-analyzed AD-only GWAS dataset to train scores weighted specifically to AD. The second score, named PRS_{AD+} (Figure 1: green), is trained using a common factor GWAS which incorporates childhood onset asthma and general allergy GWASs in addition to the meta-analyzed AD GWAS. The third model, named PRS_{AD++} (Figure 1: yellow), combines the PRS_{AD+} with GRS_{FLG} (*FLG* genetic risk score [Figure 1: blue]) for the presence of at least one of 4 well characterized loss-of-function *FLG* mutations. The comparison of the three alternative PRS models is to allow us to evaluate (i) if there is additional information to be gleaned from atopy-general rather than AD-specific GWAS signals (noting that some of the gain may arise from larger sample sizes rather than true pleiotropic genetic effects); and (ii) the added value of specific *FLG* LOF variants that are known to carry high risk for AD.

External AD GWAS

Summary statistics from external training GWASs were used to derive PRS models and are summarized in Table S2. Effect sizes for AD risk variants were derived by inverse-variance meta-analysis (METAL software)⁵⁰ for two AD GWASs of European-ancestry subjects: 1) The EARly Genetics and Lifecourse Epidemiology (EAGLE) Eczema Consortium's GWAS¹¹ (European ancestry summary statistics excluding 23andMe available at

<https://data.bris.ac.uk/data/dataset/28uchsdpmub118uex26ylacqm>; see Supplementary Note 1 from ¹¹ for case-control definitions; 23andMe summary statistics were obtained from 23andMe by visiting research.23andme.com/collaborate/#publication); and 2) The Neale Lab UK Biobank GWAS manifest for phenotype code 20002_1452 describing self-reported eczema/dermatitis⁵¹ for 9,321 cases and 351,820 controls (available at <http://www.nealelab.is/uk-biobank/>). Because the effect sizes from the UK Biobank GWAS were estimated using a linear model, prior to meta-analysis, coefficients were transformed to odds ratios using the LMOR method⁵² (see the Online Repository and Table S2 for specifics).

External Atopic Phenotype GWASs

Given overlap with other atopic diseases such as allergic rhinitis and asthma¹⁸, summary statistics from two large external GWASs - allergic disease and childhood onset asthma - were leveraged to assess whether genetic risk for these phenotypes can improve prediction of genetic risk for AD. In the GWAS of allergic disease¹⁶, cases were defined via a broad allergic disease classification – the presence of any one of asthma, hay fever (allergic rhinitis), or AD (available at https://genepi.qimr.edu.au/staff/manuelf/gwas_results/main.html). The GWAS summary statistics for childhood onset asthma³⁹ (onset before 12 years of age) were obtained from the study authors. Childhood onset asthma was used over adult onset asthma since it is more TH2 driven and associated with more epithelial barrier function genes. Table S1 include specifics on sample size and the genetic-impact correlation of these GWASs.

Common Factor GWAS_{AD+}

Recently, methods which incorporate multiple GWASs to derive a single PRS have been proposed^{53, 54} which might further improve the prediction of related diseases such as AD, asthma, and allergic rhinitis. While food allergy is a phenotype of interest for inclusion, it was not included due to the lack of a large GWAS from which to derive PRS. We implemented the software Genomic Structural Equation Modeling (Genomic SEM) to produce a common-factor GWAS for AD, childhood onset asthma, and general allergies which we refer to as the 'a-factor GWAS' to build the downstream PRS_{AD+}. Genomic SEM accounts for overlaps between subjects included in the constituent GWASs⁵³ (an important consideration for our study, given that the same subjects from the UK Biobank were included in the AD, asthma and general allergies GWAS). The effective sample size of the common-factor GWAS when implementing LDpred was back-calculated using the averaging approach derived in Mallard et al., 2019⁵⁵ (see the Online Repository).

PRS Validation Data from ADRN

Our study's primary purpose was to estimate PRS for a large group of unrelated European-ancestry Americans (EA) from the Atopic Dermatitis Research Network (ADRN), and to assess PRS prediction of AD risk and AD severity. All samples used for this study were obtained following written informed consent from participants. The University of Colorado, Johns Hopkins University, National Jewish Health, Oregon Health & Science University, University of California San Diego, Boston Children's Hospital, Northwestern University, Ann & Robert H. Lurie Children's Hospital of Chicago, University of Rochester Medical Center, Children's Hospital Los Angeles,

Children's Hospital of Philadelphia, and Mount Sinai School of Medicine Institutional Review Boards approved the conduct of this study.

GWAS array data were generated in two batches: (1) 793 samples (683 cases and 110 controls) genotyped on the Illumina Multi-Ethnic Global Array (MEGA) genotyping chip, and (2) 833 subjects (594 cases and 239 controls) genotyped on the Illumina OMNI 2.5 array chip⁵⁶. Sample quality control steps included checks for duplicates and first- or second-degree relationships (resulting in the exclusion of 7 subjects) and principal component analysis (PCA) to verify European ancestry (no subjects were excluded). We imputed the ADRN GWAS array data separately for each batch to the TOPMed Freeze5 reference panel on the Michigan Imputation Server⁵⁷. Post-imputation, variants with low minor allele frequency ($MAF < 0.01$) and genotype probability (< 0.9) were removed within each batch. The two batches were then merged to a common set of 5,663,079 variants. Details on quality control and genotype imputation steps are available in the Online Repository. The clinical characteristics of the 1,619 ADRN subjects (1,274 cases and 345 non-atopic controls) available for PRS estimation, including measures of AD severity are further discussed below and are summarized in Figures S1-S2 and Table S4. Cases were defined using AD standard diagnosis criteria with the extra requirement that subjects less than four years of age presented AD for at least six months (to avoid misdiagnosis). The non-atopic control subjects were defined as having no individual or family history of atopy and average total IgE less than 100 kU/L²⁰.

PRS Model Derivation and Selection

We used three alternative linkage disequilibrium (LD) modeling methods in LDpred⁵⁸ relying on the above mentioned external GWAS results while computing PRS for different parameter settings. These three models include 1) LD pruning followed by p-value thresholding (P+T); 2) LDpred where posterior mean effect sizes are estimated given a proportion of causal markers and accounting for LD; and 3) LDpred-inf where the LDpred model is specialized to an infinitesimal prior, and all variants are considered causal. Because the complex genetic architecture of AD has not yet been well characterized, we implemented all three models across LDpred's standard p-value threshold grid (1, 3×10^{-1} , 1×10^{-1} , 3×10^{-2} , 1×10^{-2} , 3×10^{-3} , 1×10^{-3} , 3×10^{-4} , 1×10^{-4} , 3×10^{-5} , 1×10^{-5} , 1×10^{-6} , 1×10^{-7} , 1×10^{-8} for the P+T model) and proportion of causal variants grid (1, 3×10^{-1} , 1×10^{-1} , 3×10^{-2} , 1×10^{-2} , 3×10^{-3} , 1×10^{-3} for the LDpred model). We used the 1,619 ADRN EA subjects for the LD reference panel. To account for the unbalanced case and control count of the training GWASs, we computed the effective samples size (N_{eff}) using the relevant variance inflation factor: $N_{\text{eff}} = 4/(1/N_{\text{cases}} + 1/N_{\text{controls}})^{59}$.

We compared results across these different model types and thresholds to determine the best approach for each of the three PRSs. Likelihood-ratio-tests (LRTs) were used to compare model fit for all pairs of models. Figure S3 illustrate the model selection process for PRS_{AD} in which the LDpred model (proportion of causal variants = 3×10^{-2}) was the selected based on these metrics. In order to visually interpret disease risk by strata, we include violin boxplots and quantile plots which were constructed using relative quantile status to distinguish AD cases and controls⁶⁰. Logistic regression models were used to validate each of the three PRSs in the ADRN data (N=1,274 cases, N=1,619 of European ancestry) where PRS was used as the predictor of case-

control status. Models were ranked on the basis of area under the curve (AUC)⁶¹, odds ratio (OR), Nagelkerke R^2 , and McFadden R^2 . These metrics are widely used and provide slightly different methods for evaluation of PRS prediction accuracy^{58, 60}.

Contribution of *FLG* mutations to the PRS_{AD++}

Because *FLG* LOF mutations⁴⁸ were not included in the general PRS (see Table S5), we used whole genome sequence data, available for 758 ADRN subjects (described in the Online Repository), to assess enrichment of *FLG* mutations by PRS quantile. We used carrier status for any *FLG* LOF variant, i.e. individuals with an alternate genotype for at least one of 2282del4³⁸, R501X^{11, 38, 51}, S3247X^{6, 25}, or R2447X^{6, 25} were coded as 1 (carrier), and individuals without any of these LOF variants were coded as 0 (non-carrier). This *FLG* indicator was standardized and combined with the standardized PRS_{AD+} for the 758 individuals with WGS data to create a composite PRS_{AD++}.

AD Severity Correlations with PRS_{AD}, PRS_{AD+}, and PRS_{AD++}

We used several measures to test for association between PRS and AD severity (Figures S1-S2 and Table S4). The total eosinophil count (cells/mm³ – calculated from the “CBC with differential” blood test), log-transformed values for total serum IgE (tIgE), infant age of onset (AD onset before one year of age), eosinophil count, Rajka-Langeland (RL) scores, and Eczema Area and Severity Index (EASI) scores (a standardized system used to grade an individual's degree of severity on a scale from 0 to 72⁶²) were used in this analysis. Prior to log-transforming and adjusting individual severity measure values for age and sex (using linear model residuals), we added 1 to each EASI score to avoid taking the log₁₀ of 0. A Box-Cox transformation with a lambda

318 of 1.5 was applied to the Rajka-Langeland (RL) score to normalize the distribution. In
319 order to assess prediction of *moderate* and *severe* AD, we classified individuals in the
320 ADRN based on their adjusted EASI scores relative to the following definition of severity
321 strata: clear = 0.0, $0.0 < \text{mild} < 6.0$, $6.0 \leq \text{moderate} < 23.0$, $23.0 \leq \text{severe} \leq 72.0$ ⁶³,
322 transformed to the $\log_{10}(\text{EASI}+1)$ scale. The distribution of AD severity is illustrated in
323 Figure S1 and classification totals of the 1,619 individuals are as follows: Control = 345,
324 Clear AD = 2, Mild AD = 447, Moderate AD = 597, Severe AD = 228.

Results

PRS Model Selection

Accuracy of the various AD PRS models are summarized in Figures S5-S10 and Table S7. Using LDpred's default array of thresholds for p-values (P+T models) and proportion of causal variants (LDpred models), AD was best predicted by the LDpred model with the proportion of causal markers set to 0.03 (Figures S3). The worst performing models included the P+T models with highly stringent thresholds (e.g. $p = 1 \times 10^{-7}$). The most inclusive models, such as the LDpred infinitesimal and P+T $p = 1$ models, fell in between. These results regarding model selection suggest that there is some middle ground of how many variants with weak effect sizes are relevant towards the prediction of AD.

PRS_{AD}, PRS_{AD+} and PRS_{AD++}

The standardized PRS_{AD} followed a normal distribution and ranged 7.74 SD units from -2.62 to 5.12 (Figure 2). The model had an AUC = 0.64, describing a 0.64 probability that the PRS model is able to correctly distinguish between AD cases and controls, based solely on PRS and no other clinical risk factors. When comparing controls to only individuals with severe AD the AUC increased to 0.70.

With the addition of related phenotypes in the common factor training dataset (PRS_{AD+}) the AUC improved from 0.64 to 0.71, and further combining this score with the GRS_{FLG} shown in Figure S9 yielded a larger AUC of 0.76 (PRS_{AD++}). Moreover, the scores explained most of the SNP-based heritability (PRS_{AD+}: Nagelkerke $R^2 = 0.132$ and McFadden $R^2 = 0.086$) captured by the training AD GWAS ($h^2_{\text{SNP}} = 0.135$, Table S1). In terms of effect size, the PRS_{AD} produced an OR [95% CI] = 1.70 [1.49, 1.93]

which improved to 3.23 [2.57, 4.47] for the PRS_{AD++}. These standardized PRSs are equivalent to Z-scores and a 1-unit (1SD) increase in the PRS_{AD++} corresponded to an OR = 3.23 and a 3-unit (3SD) increase resulted in an OR = $3.23^3 = 33.7$. When including both age and sex as covariates, the AUC for PRS_{AD} improved from 0.64 to 0.71, the AUC for PRS_{AD+} improved from 0.71 to 0.75, and the AUC for PRS_{AD++} improved from 0.76 to 0.80 (Table S8).

When comparing PRS quantiles in Figure 3, we found that belonging to the upper quantiles (60%-100%) relative to the middle quantile (40%-50%) trended with an OR greater than one, and this trend strengthened for PRS_{AD+} and PRS_{AD++}. The lower quantiles [0%-40%] followed this trend with ORs consistently below one. Notably, the PRS_{AD++} quantile plot illustrates that belonging to the top quantile relative to belonging to the middle quantile had a large OR [95% CI] = 10.56 [3.01, 36.99] (top right Figure 3)

PRS correlates with AD severity

In addition to tracking phenotypic outcomes, PRS was positively correlated with disease severity among AD affected individuals (Table 1). The linear model between log-transformed EASI and PRS had a positive slope of β [95% CI] = 0.036 [0.015, 0.057] ($p < 0.001$). All regressions between PRS and severity measures (EASI, tlgE, Eosinophils, RL) and age of onset were statistically significant. The R^2 increased for each severity measure along the progression from PRS_{AD} to PRS_{AD+} to PRS_{AD++}.

FLG mutations and the PRSs

The PRS_{AD} and PRS_{AD+} models segregated a considerable number of AD cases without considering LOF *FLG* mutations into the upper quantiles, and in Figure 4 we examine *FLG* carrier frequency by quantile for each PRS distribution (Figure 4). For PRS_{AD} on the bottom-left of Figure 4, there was a trend of increasing prevalence of *FLG* LOF carriers toward the upper quantiles (mean PRS_{AD} without *FLG* mutation = -0.213; mean PRS_{AD} with *FLG* mutation = 0.349; difference of means = 0.562; t-test $p < 1 \times 10^{-11}$). In comparing the bottom-left (PRS_{AD}) and bottom-middle plots (PRS_{AD+}) of Figure 4, we did not observe an increase in separation of PRS by *FLG* carrier status (mean PRS_{AD+} without *FLG* mutation = -0.171; mean PRS_{AD+} with *FLG* mutation = 0.290; difference of means = 0.461; t-test $p < 1 \times 10^{-8}$). This was noteworthy since the progression from AD to PRS_{AD+} introduced a 0.64 to 0.71 (+0.07) improvement in AUC. Therefore, this improvement in accuracy from training on the common factor GWAS compared to the AD-only GWAS seemed to be driven by signals different from epidermal barrier deficiency via *FLG* LOF. As expected, by explicitly adding in the *FLG* indicator with PRS_{AD++}, there was a distinct shift towards nearly all *FLG* LOF carriers being placed in the upper PRS quantiles (bottom-right of Figure 4: mean PRS_{AD++} without *FLG* mutation = -0.432; mean PRS_{AD++} with *FLG* mutation = 1.387; difference of means = 1.818; t-test $p < 1 \times 10^{-15}$) which resulted in a 0.71 to 0.76 (+0.05) improvement in AUC. Although the first two PCs were marginally correlated with PRSs, the PCs were not predictive of AD risk (Table S6), suggesting that population substructure (as would be captured by these PCs) is not a significant contributor to the trend in enrichment of *FLG* mutation carriers in the top PRS quantile. An auxiliary analysis in which we

390 compared genetic scores for the EDC versus scores excluding the EDC suggested that
391 *FLG* variants stand out as the primary signal within the EDC (see the section titled “PRS
392 and the EDC” in the online repository).

393

Discussion

The present study quantifies predisposed genetic risk using multiple methods and training datasets. Consistent with²⁹, our findings support the utility of using genetic scores to predict AD and to identify high-risk neonates. We illustrate how prediction accuracy can be optimized through the improvements across PRS_{AD}, PRS_{AD+}, and PRS_{AD++}. Specifically, the PRS_{AD+} model outlines the utility of a training dataset that includes related atopic phenotypes, and the PRS_{AD++} model emphasizes the distinct signal of *FLG* LOF variants. Comparing these three genetic scores furthers our understanding of the complex genetic architecture underlying AD (through the evaluation of *FLG* vs non-*FLG* genetic components, multiple training datasets, and model selection across an array of causal variant thresholds) and quantifies the association between genetics and disease severity.

The ability to identify high risk individuals at an early age might open the door for preventative measures and three small randomized trials have suggested a reduced risk of AD development by 32-50% from the daily application of emollients in the first few months of life³²⁻³⁴. However, subsequent studies in larger cohorts failed to substantiate these findings of reduced risk of AD and dampened enthusiasm for easy-to-use and low-cost⁴⁰ topical therapies⁴¹⁻⁴³. Investigators continue to study the utility of emollients for AD prevention^{44, 45} and there remains a need for high quality data on the efficacy of primary prevention strategies⁴⁶. AD clinical trials have commonly used family history to identify high risk infants, and the addition of PRS would enhance the accuracy of inclusion criteria for future studies. For example, PRS might be useful in investigating whether the efficacy of emollient therapy differs as a function of genetic determinants of

skin barrier dysfunction compared to patients with low genetic risk and/or an AD phenotype primarily driven by Th2 imbalance. In addition, the positive correlation between PRS and AD severity suggests that PRS could be used to better understand the genetic predisposition to not only the development of AD, but also its severity. As exemplified by the AUCs calculated (without covariates) for food allergy (0.74), asthma (0.69) and allergic rhinitis (0.69) by Simard and colleagues²⁹, PRS of AD has a broad scope of potential utility for predicting other allergic diseases as well.

In the context of clinical applications of PRS, there are imperative considerations regarding the social inequality of PRS informed treatment options⁶⁴. As has been pointed out by many in the field, a critical ethical consideration of PRS stems from evidence that PRS can be biased and unreliable when there is misalignment between ethnicities of the target population and the GWAS⁶⁵. We are alarmed by the lack of non-European GWASs pertaining to AD and related phenotypes because the power harnessed in the large sample sizes from these external training datasets is essential to generating meaningful PRS calculations. This concern is compounded by increased morbidity of AD in ethnic minorities such as African Americans³⁷ and evidence that AD likely has differing genetic architecture across ethnicities; for example, multiple studies have noted the differences in frequencies of *FLG* mutations associating with AD in individuals of European and non-European ancestry⁶⁶⁻⁶⁹.

Another limitation of our study lies in the definition of cases and controls. The inclusion criteria for cases might be biased toward including persistent AD rather than early infancy or transient AD. As aforementioned, all of the controls in this study were non-atopic which greatly limited our ability to disentangle atopy versus risk for AD. On

one hand, these limitations might explain why the general allergy GWAS (Figure S6) was a more effective training dataset than the AD GWAS (although some of the increase in prediction accuracy is likely due to the general allergy GWAS having an effective sample size ~2.3 times larger than the AD GWAS). In addition, some ADRN subjects have related comorbidities (51% of AD cases and 0% of controls are asthmatic) which might inflate the accuracy of these PRSs within the context of the atopic march. The comorbid nature of atopic diseases and the increased accuracy from the general allergy training dataset might be explained by recent findings showing AD and allergy sensitization are strong atopic disease risk markers early in life⁷⁰.

Identifying ideal control subjects for AD is a pervasive challenge: when using population-based controls, it is extremely difficult to ascertain when AD onset can occur throughout one's lifespan, and both atopy and AD are common diseases in the general population. While population controls are commonly used in GWAS for gene discovery, we note the challenges here in evaluating true prediction accuracy. Because our primary measures of severity (EASI and RL) were measured at the time of enrollment, it is important to acknowledge that severity ratings might vary over time and depend on the course of treatment (e.g. a patient who needs systemic medications to achieve a mild EASI score is not mild but severe).

In the future, we hope to see further improvements in the predictive accuracy and breadth of these genetic models. Specifically, we urge the following areas of potential growth:

- 1) Larger effective GWAS sample sizes (of all ethnicities) will improve the accuracy of training datasets. Increasing effective sample sizes from tens-of-thousands to hundreds-of-thousands could greatly improve PRS accuracy of AD.
- 2) High standards for GWAS phenotype accuracy, as we suspect that the notable differences between the meta-analyzed summary statistics may be attributable to variable case definitions (*e.g.* doctor diagnosed vs self-reported). This includes better coverage and distinction of sub-phenotypes of AD within the GWAS catalog.
- 3) AD outcomes are heavily influenced by the environment, and prediction could be improved by incorporating non-genetic covariates into these PRS models. While we explicitly focused on assessing genetic scores and their correlations with severity measures, covariates (that would be available for neonates) such as age, sex and parents' ethnicity have been shown to be useful for the prediction of AD²⁹. In our study, age was a more informative covariate than sex, and the inclusion of both variables as covariates in the model improved the AUCs for PRS_{AD} by +0.07, PRS_{AD+} by +0.04, and PRS_{AD++} by +0.04. Downstream measures such as tlgE or total eosinophil count would substantially improve model accuracy and likely result in almost perfect case-control separation (given the non-atopic control definition), leaving little room to assess the role of genetically derived risk.
- 4) The implementation of developing possibly superior statistical scoring methods⁷¹⁻⁷³ might allow for models that are even more specifically tailored to the complex genetic architecture of AD.

5) Large non-European training GWAS datasets and new PRS modeling approaches suited for admixed populations need to be developed and implemented (see online repository for auxiliary PRS analysis in African Americans).

In conclusion, this study presents a thorough framework for the genetic prediction of complex disease. We reason that methods of AD care could greatly benefit from applications of genetic scoring, and that there is room to grow in our ability to optimally predict AD. AD PRS associates with AD severity and was improved with a common-factor GWAS of AD, childhood-onset asthma, and general allergic disease exemplifying the entangled genetic architecture of atopic diseases. While polygenic scoring could play a special role in identifying high-risk individuals without *FLG* mutations, these variants continue to be a primary focus for atopic disease prediction.

References

1. Hanifin JM, Reed ML, Prevalence E, Group IW. A Population-Based Survey of Eczema Prevalence in the United States. *Dermatitis* 2007; 18:82-91.
2. Shaw TE, Currie GP, Koudelka CW, Simpson EL. Eczema Prevalence in the United States: Data from the 2003 National Survey of Children's Health. *Journal of Investigative Dermatology* 2011; 131:67-73.
3. Deckers IAG, McLean S, Linssen S, Mommers M, van Schayck CP, Sheikh A. Investigating International Time Trends in the Incidence and Prevalence of Atopic Eczema 1990–2010: A Systematic Review of Epidemiological Studies. *PLOS ONE* 2012; 7:e39803.
4. Drucker AM, Wang AR, Li W-Q, Sevetson E, Block JK, Qureshi AA. The Burden of Atopic Dermatitis: Summary of a Report for the National Eczema Association. *Journal of Investigative Dermatology* 2017; 137:26-30.
5. Bickers DR, Lim HW, Margolis D, Weinstock MA, Goodman C, Faulkner E, et al. The burden of skin diseases: 2004: A joint project of the American Academy of Dermatology Association and the Society for Investigative Dermatology. *Journal of the American Academy of Dermatology* 2006; 55:490-500.
6. Smith Begolka W, Chovatiya R, Thibau IJ, Silverberg JI. Financial Burden of Atopic Dermatitis Out-of-Pocket Health Care Expenses in the United States. *Dermatitis* 2020.
7. Chiesa Fuxench ZC, Block JK, Boguniewicz M, Boyle J, Fonacier L, Gelfand JM, et al. Atopic Dermatitis in America Study: A Cross-Sectional Study Examining the Prevalence and Disease Burden of Atopic Dermatitis in the US Adult Population. *J Invest Dermatol* 2019; 139:583-590.
8. Silverberg JI, Gelfand JM, Margolis DJ, Boguniewicz M, Fonacier L, Grayson MH, et al. Patient burden and quality of life in atopic dermatitis in US adults: A population-based cross-sectional study. *Ann Allergy Asthma Immunol* 2018; 121:340-347.
9. Barnes KC. An update on the genetics of atopic dermatitis: scratching the surface in 2009. *The Journal of allergy and clinical immunology* 2010; 125:16-31.
10. Kantor R, Silverberg JI. Environmental risk factors and their role in the management of atopic dermatitis. *Expert Review of Clinical Immunology* 2017; 13:15-26.
11. Paternoster L, Standl M, Waage J, Baurecht H, Hotze M, Strachan DP, et al. Multi-ancestry genome-wide association study of 21,000 cases and 95,000 controls identifies new risk loci for atopic dermatitis. *Nature Genetics* 2015; 47:1449.
12. Ober C, Yao T-C. The genetics of asthma and allergic disease: a 21st century perspective. *Immunological reviews* 2011; 242:10-30.
13. Bataille V, Lens M, Spector TD. The use of the twin model to investigate the genetics and epigenetics of skin diseases with genomic, transcriptomic and methylation data. *Journal of the European Academy of Dermatology and Venereology* 2012; 26:1067-1073.
14. Bantz SK, Zhu Z, Zheng T. The Atopic March: Progression from Atopic Dermatitis to Allergic Rhinitis and Asthma. *Journal of clinical & cellular immunology* 2014; 5:202.
15. Davidson WF, Leung DYM, Beck LA, Berin CM, Boguniewicz M, Busse WW, et al. Report from the National Institute of Allergy and Infectious Diseases workshop on “Atopic dermatitis and the atopic march: Mechanisms and interventions”. *Journal of Allergy and Clinical Immunology* 2019; 143:894-913.

16. Ferreira MA, Vonk JM, Baurecht H, Marenholz I, Tian C, Hoffman JD, et al. Shared genetic origin of asthma, hay fever and eczema elucidates allergic disease biology. *Nature Genetics* 2017; 49:1752.
17. Zhu Z, Lee PH, Chaffin MD, Chung W, Loh P-R, Lu Q, et al. A genome-wide cross-trait analysis from UK Biobank highlights the shared genetic architecture of asthma and allergic diseases. *Nature Genetics* 2018; 50:857-864.
18. Kanchan K, Clay S, Irizar H, Bunyavanich S, Mathias RA. Current Insights Into The Genetics Of Food Allergy. *J Allergy Clin Immunol*, in press.
19. Schmitt J, Schakel K, Schmitt N, Meurer M. Systemic treatment of severe atopic eczema: a systematic review. *Acta Derm Venereol* 2007; 87:100-111.
20. Beck LA, Boguniewicz M, Hata T, Schneider LC, Hanifin J, Gallo R, et al. Phenotype of atopic dermatitis subjects with a history of eczema herpeticum. *The Journal of allergy and clinical immunology* 2009; 124:260-269.e2697.
21. Simpson EL, Villarreal M, Jepson B, Rafaels N, David G, Hanifin J, et al. Patients with Atopic Dermatitis Colonized with *Staphylococcus aureus* Have a Distinct Phenotype and Endotype. *J Invest Dermatol* 2018; 138:2224-2233.
22. Broccardo CJ, Mahaffey S, Schwarz J, Wruck L, David G, Schlievert PM, et al. Comparative proteomic profiling of patients with atopic dermatitis based on history of eczema herpeticum infection and *Staphylococcus aureus* colonization. *The Journal of allergy and clinical immunology* 2011; 127:186-194.e11.
23. Wray NR, Kempner KE, Hayes BJ, Goddard ME, Visscher PM. Complex Trait Prediction from Genome Data: Contrasting EBV in Livestock to PRS in Humans. *Genomic Prediction* 2019; 211:1131-1141.
24. Torkamani A, Wineinger NE, Topol EJ. The personal and clinical utility of polygenic risk scores. *Nature Reviews Genetics* 2018; 19:581-590.
25. Lambert SA, Abraham G, Inouye M. Towards clinical utility of polygenic risk scores. *Human Molecular Genetics* 2019; 28:R133-R142.
26. Khera AV, Chaffin M, Aragam KG, Haas ME, Roselli C, Choi SH, et al. Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. *Nature Genetics* 2018; 50:1219-1224.
27. Paternoster L, Savenije OEM, Heron J, Evans DM, Vonk JM, Brunekreef B, et al. Identification of atopic dermatitis subgroups in children from 2 longitudinal birth cohorts. *The Journal of allergy and clinical immunology* 2018; 141:964-971.
28. Johansson Å, Rask-Andersen M, Karlsson T, Ek WE. Genome-wide association analysis of 350 000 Caucasians from the UK Biobank identifies novel loci for asthma, hay fever and eczema. *Human molecular genetics* 2019; 28:4022-4041.
29. Simard M, Madore A-M, Girard S, Wasserman S, Duan Q, Subbarao P, et al. Polygenic risk score for atopic dermatitis in the Canadian population. *Journal of Allergy and Clinical Immunology* 2020; 147:406 - 409.
30. Clark H, Granell R, Curtin JA, Belgrave D, Simpson A, Murray C, et al. Differential associations of allergic disease genetic variants with developmental profiles of eczema, wheeze and rhinitis. *Clinical & Experimental Allergy* 2019; 49:1475-1486.
31. Løset M, Brown SJ, Saunes M, Hveem K. Genetics of Atopic Dermatitis: From DNA Sequence to Clinical Relevance. *Dermatology* 2019; 235:355-364.

32. Simpson EL, Chalmers JR, Hanifin JM, Thomas KS, Cork MJ, McLean WHI, et al. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. *The Journal of allergy and clinical immunology* 2014; 134:818-823.
33. Horimukai K, Morita K, Narita M, Kondo M, Kitazawa H, Nozaki M, et al. Application of moisturizer to neonates prevents development of atopic dermatitis. *Journal of Allergy and Clinical Immunology* 2014; 134:824-830.e826.
34. Lowe AJ, Su JC, Allen KJ, Abramson MJ, Cranswick N, Robertson CF, et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study. *British Journal of Dermatology* 2018; 178:e19-e21.
35. Bin L, Leung DYM. Genetic and epigenetic studies of atopic dermatitis. *Allergy, Asthma & Clinical Immunology* 2016; 12:52.
36. Boyle EA, Li YI, Pritchard JK. An Expanded View of Complex Traits: From Polygenic to Omnigenic. *Cell* 2017; 169:1177-1186.
37. Daya M, Barnes KC. African American ancestry contribution to asthma and atopic dermatitis. *Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology* 2019; 122:456-462.
38. Rodríguez E, Baurecht H, Herberich E, Wagenpfeil S, Brown SJ, Cordell HJ, et al. Meta-analysis of filaggrin polymorphisms in eczema and asthma: Robust risk factors in atopic disease. *Journal of Allergy and Clinical Immunology* 2009; 123:1361-1370.e1367.
39. Pividori M, Schoettler N, Nicolae DL, Ober C, Im HK. Shared and distinct genetic risk factors for childhood-onset and adult-onset asthma: genome-wide and transcriptome-wide studies. *The Lancet Respiratory Medicine* 2019; 7:509-522.
40. Xu S, Immaneni S, Hazen GB, Silverberg JI, Paller AS, Lio PA. Cost-effectiveness of Prophylactic Moisturization for Atopic Dermatitis. *JAMA Pediatrics* 2017; 171:e163909-e163909.
41. Chalmers JR, Haines RH, Bradshaw LE, Montgomery AA, Thomas KS, Brown SJ, et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. *Lancet* 2020; 395:962-972.
42. Skjerven HO, Rehbinder EM, Vettukattil R, LeBlanc M, Granum B, Haugen G, et al. Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial. *Lancet* 2020; 395:951-961.
43. Perrett KP, Peters RL. Emollients for prevention of atopic dermatitis in infancy. *The Lancet* 2020; 395:923-924.
44. Lowe A, Su J, Tang M, Lodge CJ, Matheson M, Allen KJ, et al. PEBBLES study protocol: a randomised controlled trial to prevent atopic dermatitis, food allergy and sensitisation in infants with a family history of allergic disease using a skin barrier improvement strategy. *BMJ Open* 2019; 9:e024594.
45. Kelleher MM, Cro S, Cornelius V, Axon E, Lodrup Carlsen KC, Skjerven HO, et al. Skincare interventions in infants for preventing eczema and food allergy. *Cochrane Database of Systematic Reviews* 2020.
46. Bawany F, Beck LA, Järvinen KM. Halting the March: Primary Prevention of Atopic Dermatitis and Food Allergies. *J Allergy Clin Immunol Pract* 2020; 8:860-875.
47. O'Regan GM, Sandilands A, McLean WHI, Irvine AD. Filaggrin in atopic dermatitis. *Journal of Allergy and Clinical Immunology* 2009; 124:R2-R6.

48. Weidinger S, O'Sullivan M, Illig T, Baurecht H, Depner M, Rodriguez E, et al. Filaggrin mutations, atopic eczema, hay fever, and asthma in children. *Journal of Allergy and Clinical Immunology* 2008; 121:1203-1209.e1201.
49. Sandilands A, Smith FJD, Irvine AD, Irwin McLean WH. Filaggrin's Fuller Figure: A Glimpse into the Genetic Architecture of Atopic Dermatitis. *Journal of Investigative Dermatology* 2007; 127:1282-1284.
50. Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide association scans. *Bioinformatics (Oxford, England)* 2010; 26:2190-2191.
51. Neale-Lab. GWAS round 2. <http://www.nealelab.is/uk-biobank/>, 2018.
52. Lloyd-Jones LR, Robinson MR, Yang J, Visscher PM. Transformation of Summary Statistics from Linear Mixed Model Association on All-or-None Traits to Odds Ratio. *Genetics* 2018; 208:1397-1408.
53. Grotzinger AD, Rhemtulla M, de Vlaming R, Ritchie SJ, Mallard TT, Hill WD, et al. Genomic SEM Provides Insights into the Multivariate Genetic Architecture of Complex Traits. *bioRxiv* 2018:305029.
54. Krapohl E, Patel H, Newhouse S, Curtis CJ, von Stumm S, Dale PS, et al. Multi-polygenic score approach to trait prediction. *Molecular Psychiatry* 2018; 23:1368-1374.
55. Mallard TT, Linnér RK, Okbay A, Grotzinger AD, de Vlaming R, Meddens SFW, et al. Not just one p; Multivariate GWAS of psychiatric disorders and their cardinal symptoms reveal two dimensions of cross-cutting genetic liabilities. *bioRxiv* 2019:603134.
56. Johnston HR, Hu Y-J, Gao J, O'Connor TD, Abecasis GR, Wojcik GL, et al. Identifying tagging SNPs for African specific genetic variation from the African Diaspora Genome. *Scientific Reports* 2017; 7:46398.
57. Das S, Forer L, Schönherr S, Sidore C, Locke AE, Kwong A, et al. Next-generation genotype imputation service and methods. *Nat Genet* 2016; 48:1284-1287.
58. Vilhjálmsson Bjarni J, Yang J, Finucane Hilary K, Gusev A, Lindström S, Ripke S, et al. Modeling Linkage Disequilibrium Increases Accuracy of Polygenic Risk Scores. *The American Journal of Human Genetics* 2015; 97:576-592.
59. Hsieh FY, Lavori PW, Cohen HJ, Feussner JR. An Overview of Variance Inflation Factors for Sample-Size Calculation. *Evaluation & the Health Professions* 2003; 26:239-257.
60. Choi SW, Heng Mak TS, O'Reilly PF. A guide to performing Polygenic Risk Score analyses. *bioRxiv* 2018:416545.
61. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. *Radiology* 1982; 143:29-36.
62. Hanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ, Graeber M, et al. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. *Experimental Dermatology* 2001; 10:11-18.
63. Chopra R, Vakharia PP, Sacotte R, Patel N, Immaneni S, White T, et al. Severity strata for Eczema Area and Severity Index (EASI), modified EASI, Scoring Atopic Dermatitis (SCORAD), objective SCORAD, Atopic Dermatitis Severity Index and body surface area in adolescents and adults with atopic dermatitis. *British Journal of Dermatology* 2017; 177:1316-1321.

64. Martin AR, Kanai M, Kamatani Y, Okada Y, Neale BM, Daly MJ. Clinical use of current polygenic risk scores may exacerbate health disparities. *Nature Genetics* 2019; 51:584-591.
65. Martin AR, Gignoux CR, Walters RK, Wojcik GL, Neale BM, Gravel S, et al. Human Demographic History Impacts Genetic Risk Prediction across Diverse Populations. *The American Journal of Human Genetics* 2017; 100:635-649.
66. Margolis DJ, Gupta J, Apter AJ, Ganguly T, Hoffstad O, Papadopoulos M, et al. Filaggrin-2 variation is associated with more persistent atopic dermatitis in African American subjects. *The Journal of allergy and clinical immunology* 2014; 133:784-789.
67. Akiyama M. FLG mutations in ichthyosis vulgaris and atopic eczema: spectrum of mutations and population genetics. *British Journal of Dermatology* 2010; 162:472-477.
68. Winge MCG, Bilcha KD, Liedén A, Shibeshi D, Sandilands A, Wahlgren CF, et al. Novel filaggrin mutation but no other loss-of-function variants found in Ethiopian patients with atopic dermatitis. *British Journal of Dermatology* 2011; 165:1074-1080.
69. Gao P-S, Rafaels NM, Hand T, Murray T, Boguniewicz M, Hata T, et al. Filaggrin mutations that confer risk of atopic dermatitis confer greater risk for eczema herpeticum. *The Journal of allergy and clinical immunology* 2009; 124:507-513.e5137.
70. Tran MM, Lefebvre DL, Dharma C, Dai D, Lou WYW, Subbarao P, et al. Predicting the atopic march: Results from the Canadian Healthy Infant Longitudinal Development Study. *J Allergy Clin Immunol* 2018; 141:601-607.e608.
71. Mak TSH, Porsch RM, Choi SW, Zhou X, Sham PC. Polygenic scores via penalized regression on summary statistics. *Genetic Epidemiology* 2017; 41:469-480.
72. Privé F, Vilhjálmsson BJ, Aschard H, Blum MGB. Making the most of Clumping and Thresholding for polygenic scores. *bioRxiv* 2019:653204.
73. Privé F, Arbel J, Vilhjálmsson BJ. LDpred2: better, faster, stronger. *bioRxiv* 2020:2020.2004.2028.066720.
74. Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-generation PLINK: rising to the challenge of larger and richer datasets. *GigaScience* 2015; 4:7-7.
75. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MAR, Bender D, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. *American journal of human genetics* 2007; 81:559-575.
76. Manichaikul A, Mychaleckyj JC, Rich SS, Daly K, Sale M, Chen W-M. Robust relationship inference in genome-wide association studies. *Bioinformatics* 2010; 26:2867-2873.
77. Conomos MP, Miller MB, Thornton TA. Robust inference of population structure for ancestry prediction and correction of stratification in the presence of relatedness. *Genetic epidemiology* 2015; 39:276-293.
78. Brody JA, Morrison AC, Bis JC, O'Connell JR, Brown MR, Huffman JE, et al. Analysis commons, a team approach to discovery in a big-data environment for genetic epidemiology. *Nature Genetics* 2017; 49:1560-1563.
79. Marioni RE, Harris SE, Zhang Q, McRae AF, Hagenaars SP, Hill WD, et al. GWAS on family history of Alzheimer's disease. *Translational Psychiatry* 2018; 8:99.
80. Boorgula MP, Taub MA, Rafaels N, Daya M, Campbell M, Chavan S, et al. Replicated methylation changes associated with eczema herpeticum and allergic response. *Clinical Epigenetics* 2019; 11:122.

- 722 81. Rimmer A, Phan H, Mathieson I, Iqbal Z, Twigg SRF, Consortium WGS, et al.
723 Integrating mapping-, assembly- and haplotype-based approaches for calling variants in
724 clinical sequencing applications. *Nat Genet* 2014; 46:912-918.
- 725 82. Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-generation
726 PLINK: rising to the challenge of larger and richer datasets. *Gigascience* 2015; 4:7.
- 727 83. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. PLINK: a
728 tool set for whole-genome association and population-based linkage analyses. *Am J Hum*
729 *Genet* 2007; 81:559-575.
- 730 84. Danecek P, Auton A, Abecasis G, Albers CA, Banks E, DePristo MA, et al. The variant
731 call format and VCFtools. *Bioinformatics* 2011; 27:2156-2158.
- 732 85. Danecek P, McCarthy SA. BCFtools/csq: haplotype-aware variant consequences.
733 *Bioinformatics* 2017; 33:2037-2039.
- 734 86. Brown BC, Asian Genetic Epidemiology Network Type 2 Diabetes C, Ye CJ, Price AL,
735 Zaitlen N. Transethnic Genetic-Correlation Estimates from Summary Statistics.
736 *American journal of human genetics* 2016; 99:76-88.
- 737 87. Coram MA, Fang H, Candille SI, Assimes TL, Tang H. Leveraging Multi-ethnic
738 Evidence for Risk Assessment of Quantitative Traits in Minority Populations. *American*
739 *journal of human genetics* 2017; 101:218-226.
- 740

Figure Captions and Tables:

Figure 1: Workflow diagram for PRS_{AD} (orange), PRS_{AD+} (green), and PRS_{AD++} (yellow) PRS derivation and validation. Abbreviations: AD: Atopic Dermatitis, EAGLE: the EARly Genetics and Lifecourse Epidemiology (EAGLE) eczema consortium, N_{eff} = effective sample size, Genomic SEM: genomic structural equation modelling, GRS: Genetic Risk Score, GWAS: Genome Wide Association Study, LD: Linkage Disequilibrium, PRS: Polygenic Risk Score, UK Biobank: United Kingdom Biobank.

Figure 2: PRS_{AD}, PRS_{AD+}, and PRS_{AD++}: there is increased separation between cases and controls from left to right with the addition of related GWAS (PRS_{AD+}) and *FLG* mutations (PRS_{AD++}) and from top to bottom with increasing AD severity. The bottom right plot of PRS_{AD++} for severe AD vs controls has no interquartile overlap and an AUC of 0.82.

Figure 3: Quantile plots describe OR and 95% confidence intervals for each quantile relative to the median quantile (40%, 50%] as a predictor of AD case status. Noting the non-linear spacing of tick marks on the log transformed y-axis, the odds ratios illustrate the most distinction at the extreme quantiles for the PRS_{AD++}. There is notable ability of PRS – especially at the extremes – to distinguish between cases and controls for this complex disease.

Table 1: PRS_{AD}, PRS_{AD+}, and PRS_{AD++} versus adjusted severity measures. Measures for EASI, total IgE, total eosinophils, and RL were transformed and adjusted for sex, batch,

and age. See the online repository for further details. Infant age of onset refers to AD onset before one year of age.

Linear Model	Adjusted R^2	β [95% CI]	p-value
Adjusted EASI ~ PRS _{AD}	0.008	0.036 [0.015, 0.057]	9.12×10^{-4}
Adjusted EASI ~ PRS _{AD+}	0.012	0.044 [0.022, 0.066]	7.66×10^{-5}
Adjusted EASI ~ PRS _{AD++}	0.028	0.068 [0.035, 0.102]	6.55×10^{-5}
Adjusted Total IgE ~ PRS _{AD}	0.045	0.181 [0.140, 0.222]	7.93×10^{-18}
Adjusted Total IgE ~ PRS _{AD+}	0.061	0.209 [0.169, 0.250]	1.33×10^{-23}
Adjusted Total IgE ~ PRS _{AD++}	0.136	0.349 [0.286, 0.412]	1.85×10^{-25}
Adjusted Total Eosinophils ~ PRS _{AD}	0.016	0.061 [0.038, 0.084]	2.1×10^{-7}
Adjusted Total Eosinophils ~ PRS _{AD+}	0.054	0.111 [0.088, 0.133]	1.77×10^{-21}
Adjusted Total Eosinophils ~ PRS _{AD++}	0.068	0.120 [0.089, 0.152]	2.23×10^{-13}
Adjusted RL ~ PRS _{AD}	0.005	0.294 [0.073, 0.515]	9.06×10^{-3}
Adjusted RL ~ PRS _{AD+}	0.010	0.436 [0.210, 0.661]	1.60×10^{-4}
Adjusted RL ~ PRS _{AD++}	0.018	0.557 [0.217, 0.896]	1.35×10^{-3}

Logistic Regression Model	McFadden R^2	Nagelkerke R^2	AUC	OR [95% CI]	p-value
Infant Age of Onset ~ PRS _{AD}	0.023	0.041	0.608	1.45 [1.30, 1.62]	1.14×10^{-11}
Infant Age of Onset ~ PRS _{AD+}	0.031	0.054	0.622	1.55 [1.39, 1.73]	9.37×10^{-15}
Infant Age of Onset ~ PRS _{AD++}	0.085	0.143	0.697	2.07 [1.75, 2.44]	1.10×10^{-17}

Figure 4: The top 3x3 stacked bar plots present the tally of cases and controls within each quantile of these PRS distributions. Cases tend to increase in frequency toward the upper quantiles while controls are increasingly common among the lower quantiles. This trend strengthens rightward (AD to AD+ to AD++) and downward (increased severity). In the bottom 3 plots, the grey bars in the background illustrate how roughly 50% of the individuals within each quantile had WGS data for investigation of the 4 *FLG* LOF genotypes. Among individuals with WGS data, the colored lines detail the percent of subjects who are carriers for R501X, 2282del4, R2447X, and S3247X; solid lines indicate percent of cases and dashed lines represent percent of controls who are carriers within each quantile.

Acknowledgments:

Funding for this work was provided by NIH/NIAID U19 AI117673, The Atopic Dermatitis Research Network. We thank all study subjects and 23andMe their participation along with Corey Cox and Tonya M. Brunetti for technical suggestions, John Finigan for computational resource support, and Olivia Lira for technical assistance.

Journal Pre-proof

